Semaglutide enters a 622-person Phase 3 alcohol-use-disorder trial

What the source reports

The US Department of Veterans Affairs has begun a large randomised trial testing semaglutide in veterans with alcohol use disorder. The study is called CRAVE—Cessation or Reduction of Alcohol Consumption in Veterans—and is listed on ClinicalTrials.gov as a Phase 3 trial.

The registry currently lists the study as recruiting, with an estimated 622 participants at 19 locations. It records an actual start date of 28 July 2026 and an estimated completion date of 30 March 2030. Site and recruitment details can change as a study progresses.

This is an important escalation from small early studies, but it is not a positive trial result. CRAVE has only recently started, no outcome data are available, and semaglutide is not approved as a treatment for alcohol use disorder.

What the trial is actually testing

Participants will be assigned by chance to receive either weekly semaglutide or a matching placebo for 28 weeks. The semaglutide group will have dose escalation up to 2.4 mg weekly or the maximum tolerated dose. The study is double-blind, meaning participants and the study team are not intended to know who receives which treatment during the trial.

The primary outcome is not complete abstinence or weight loss. Researchers will assess whether participants achieve at least a two-level reduction in the World Health Organization drinking-risk categories across weeks 5 to 28—for example, moving from high risk to low risk.

Other measures include heavy-drinking days, drinks per drinking day, abstinent days, alcohol craving, symptoms of alcohol use disorder, quality of life, body weight and safety. Measuring several outcomes should show whether any change is broad and clinically meaningful rather than confined to one statistic.

Who the findings will represent

The planned participants are US veterans aged 18 to 80 who meet criteria for moderate or severe alcohol use disorder and are in the high or very-high WHO drinking-risk categories. The registry also requires a body mass index of at least 21 kg/m².

The exclusion criteria include current GLP-1 treatment, current medication specifically for alcohol use disorder, certain recent suicidal thoughts or behaviours, and several serious medical or psychiatric conditions. These safeguards shape who can participate and will also limit how widely the eventual findings can be generalised.

A trial in veterans can answer a major clinical question in that population. It may not automatically predict results for civilians, people at lower drinking-risk levels, those already receiving alcohol-use-disorder medication, or people excluded for health reasons.

Why researchers think semaglutide is worth testing

GLP-1 medicines affect appetite and food reward, and researchers are investigating whether related brain pathways might also influence alcohol craving and consumption. A plausible mechanism is a reason to run a trial, not proof that the medicine treats addiction.

A 2025 US randomised trial included 48 adults with alcohol use disorder who were not seeking treatment. Over nine weeks, low-dose semaglutide reduced the amount consumed in a laboratory test and was associated with fewer drinks per drinking day and lower weekly craving. It did not significantly change average drinks per calendar day or the number of drinking days.

That study supplied an encouraging signal, but its small size, short duration and selected participants made a larger, treatment-focused trial necessary.

What a 108-person trial added

A separate 2026 randomised trial studied 108 treatment-seeking adults who had alcohol use disorder and obesity. Participants received semaglutide 2.4 mg or placebo for 26 weeks, with cognitive behavioural therapy provided in both groups.

Heavy-drinking days fell by 41.1 percentage points in the semaglutide group and 26.4 points in the placebo group. The estimated difference between groups was 13.7 percentage points. Gastrointestinal adverse effects were more common with semaglutide.

The result strengthens the case for further research, but it came from one centre and only included people with obesity. It also tested semaglutide alongside behavioural therapy, so it should not be interpreted as evidence for unsupervised medication use on its own.

Phase 3 does not mean an approved treatment

Phase 3 describes the stage and intended scale of a clinical trial. It does not mean that regulators have already accepted semaglutide as safe and effective for alcohol use disorder, or that approval will follow automatically.

The new study must establish whether the benefit is large enough, consistent enough and safe enough in the population studied. Recruitment may take time, participants may discontinue, and results can differ from earlier trials.

Until those results are available and assessed, prescribing semaglutide for alcohol use disorder remains an investigational idea rather than an established indication.

What remains uncertain

CRAVE has not yet shown whether semaglutide reduces risky drinking, whether any benefit lasts after treatment, or which participants might respond. It is also unclear how much any reduction would relate to changes in craving, reward, appetite, body weight or another pathway.

The study will need careful safety interpretation because alcohol use disorder can coexist with liver, pancreas, gastrointestinal, mental-health and other medical concerns. The eligibility criteria reduce some risks but also mean that the results will not cover every person who might seek treatment.

Even a successful trial would not make semaglutide a complete response to alcohol use disorder. Medication outcomes need to be understood alongside behavioural support, existing treatments, social circumstances and each individual’s goals.

What this means for the individual

For someone living with alcohol use disorder, the start of CRAVE is evidence that the question is being taken seriously—not a reason to obtain a GLP-1 medicine or change an existing prescription. Early trial averages cannot predict an individual response.

People concerned about their drinking can speak with a qualified healthcare or alcohol-support professional about evidence-based options available now. Anyone considering a clinical trial should review the purpose, eligibility, possible risks and alternatives with the study team before deciding whether to participate.

A person’s experience and treatment goals remain central. Care should not be delayed while waiting for this trial, and a medicine prescribed for diabetes or weight management should not be repurposed without clinical supervision.

Bottom line

The 622-person CRAVE trial is the most substantial test yet of semaglutide for alcohol use disorder. Its randomised, placebo-controlled design and clinically focused drinking outcome should provide much stronger evidence than anecdotes or short pilot studies.

Earlier trials justify asking the question, but they do not settle it. The accurate headline today is that a large Phase 3 trial has begun—not that semaglutide has been shown to treat alcohol addiction.